Medline Inc. Class A common stock
Here’s whether Medline Inc. Class A common stock (MDLN) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: 50-day MA is rising (+0.29% over 10 days); RSI 38 — healthy momentum range; rising volume confirms the move (1.42x 30d avg). Concerns: below the 50-day MA (medium-term momentum negative). Currently 29.8% off its 52-week high. Score: +2/7.
MDLN is trading below its 200-day MA (—) — a key warning sign the longer-term trend is under pressure. An RSI of 38.2 sits in the neutral zone — momentum is neither stretched nor exhausted. With ~8 months of trading history, the return since first available bar is -12.8%. The current 29.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.